Business
Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update
– DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming
About this update from Cabaletta Bio, Inc.
[{"type":"text","content":"– DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming scientific meetings in mid-2022 – – Multiple abstracts accepted for presentation at upcoming ASGCT and SID Annual Meetings – – MuSK-CAART first-in-human trial on track to commence in 2022 following Fast Track Designation and IND clearance from the FDA – PHILADELPHIA, May 12, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today reported financial results for the first quarter ended March 31, 2022, and provided a business update. “The favorable safety profile from the first four cohorts in the dose escalation phase of our ongoing DesCAARTes™ Phase 1 trial supports our ability to increase in vivo DSG3-CAART exposure to treat patients diagnosed with mucosal pemphigus vulgaris. We look forward to presenting clinical and translational data from the DesCAARTes™ trial at the upcoming ASGCT and SID annual meetings. We continue to progress cohort A5 at a range of 5.0 to 7.5 billion cells. Absent any dose limiting toxicities, we believe we can advance to a dose as high as 10 to 15 billion cells as we continue to optimize our targeted cell therapy in patients with mPV,” said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta. “We are also applying our insights learned from the DesCAARTes™ trial as we plan for the initiation of our first-in-human trial of MuSK-CAART for MuSK antibody positive myasthenia gravis this year. We believe these data and learnings advance our efforts toward delivering deep, durable, and potentially curative, responses for patients with autoimmune diseases.” Pipeline Highlights and Anticipated Upcoming Milestones DSG3-CAART: Desmoglein 3 chimeric autoantibody receptor T (DSG3-CAART) cells as a potential treatment for patients with mucosal pemphigus vulgaris (mPV). DesCAARTes™ Trial Progressing in Cohort A5: The cohort A5 dose range is 5.0 to 7.5 billion DSG3-CAART cells administered in two fractionated infusions. Assuming no dose limiting toxicities are observed, Cabaletta plans to provide cohort A5 one-month safety data and clinical and translational data from cohorts A3 (500 million c...